Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M68,487Revenue (TTM) $M23,816Net Margin (%)10.5Altman Z-Score1.4
Enterprise Value $M82,028EPS (TTM) $1.0Operating Margin %14.6Piotroski F-Score7
P/E(ttm)31.1Beneish M-Score-2.3Pre-tax Margin (%)9.1Higher ROA y-yY
Price/Book5.510-y EBITDA Growth Rate %-0.3Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.25-y EBITDA Growth Rate %-17.7Current Ratio0.8Lower Leverage y-yN
Price/Free Cash Flow134y-y EBITDA Growth Rate %9.3ROA % (ttm)4.1Higher Current Ratio y-yY
Dividend Yield %5.2PEG--ROE % (ttm)16.5Less Shares Outstanding y-yN
Payout Ratio %144Shares Outstanding M2,530ROIC % (ttm)14.4Gross Margin Increase y-yY

Gurus Latest Trades with AZN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNKen Fisher 2016-12-31 Reduce$25.81 - $33
($28.39)
$ 27.07-5%Reduce -1.34%1,950,999
AZNDodge & Cox 2016-09-30 Add0.3%$29.97 - $34.5
($32.68)
$ 27.07-17%Add 29.68%42,189,973
AZNNWQ Managers 2016-09-30 Add0.13%$29.97 - $34.5
($32.68)
$ 27.07-17%Add 46.57%839,815
AZNKen Fisher 2016-09-30 Add0.1%$29.97 - $34.5
($32.68)
$ 27.07-17%Add 483.39%1,977,585
AZNDodge & Cox 2016-06-30 Add0.19%$27.26 - $30.25
($29.03)
$ 27.07-7%Add 24.89%32,532,723
AZNNWQ Managers 2016-06-30 Add0.03%$27.26 - $30.25
($29.03)
$ 27.07-7%Add 13.06%572,985
AZNDavid Dreman 2016-06-30 Buy 0.02%$27.26 - $30.25
($29.03)
$ 27.07-7%New holding1,321
AZNKen Fisher 2016-06-30 Add0.01%$27.26 - $30.25
($29.03)
$ 27.07-7%Add 45.23%338,979
AZNDodge & Cox 2016-03-31 Add0.39%$27.95 - $33.95
($30.11)
$ 27.07-10%Add 121.19%26,049,650
AZNKen Fisher 2016-03-31 Add$27.95 - $33.95
($30.11)
$ 27.07-10%Add 5.33%233,409
AZNNWQ Managers 2016-03-31 Reduce$27.95 - $33.95
($30.11)
$ 27.07-10%Reduce -1.83%506,785
AZNDodge & Cox 2015-12-31 Buy 0.39%$30.47 - $34.77
($32.84)
$ 27.07-18%New holding11,777,132
AZNNWQ Managers 2015-12-31 Add0.01%$30.47 - $34.77
($32.84)
$ 27.07-18%Add 5.24%516,215
AZNKen Fisher 2015-12-31 Add0.01%$30.47 - $34.77
($32.8)
$ 27.07-17%Add 692.95%221,606
AZNNWQ Managers 2015-09-30 Add0.09%$30.28 - $34.54
($32.89)
$ 27.07-18%Add 60.04%490,535
AZNMario Gabelli 2015-09-30 Sold Out $30.28 - $34.54
($32.89)
$ 27.07-18%Sold Out0
AZNKen Fisher 2015-09-30 Buy $30.28 - $34.54
($32.89)
$ 27.07-18%New holding27,947
AZNDavid Dreman 2015-06-30 Sold Out -0.16%$31.86 - $36.68
($34.24)
$ 27.07-21%Sold Out0
AZNNWQ Managers 2015-06-30 Add0.12%$31.86 - $36.68
($34.24)
$ 27.07-21%Add 486.45%306,510
AZNMario Gabelli 2015-06-30 Reduce$31.86 - $36.68
($34.24)
$ 27.07-21%Reduce -28.81%8,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$1759.24view

Quarterly/Annual Reports about AZN:

    News about AZN:

    Articles On GuruFocus.com
    Dodge & Cox's Stock Fund 4th Quarter Commentary Jan 16 2017 
    Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly Dec 10 2016 
    8 Uncommon Stocks NWQ Managers Is Buying Dec 06 2016 
    How Could a Potential Nexium Lawsuit Affect AstraZeneca? Nov 03 2016 
    Novo Nordisk Is Being Ignored Oct 06 2016 
    Novartis Is Surviving Oct 03 2016 
    10 Stocks Dodge & Cox Keep Buying Sep 22 2016 
    Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
    Francis Chou Raises Stake in Resolute Forest Products Mar 20 2016 
    Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 

    More From Other Websites
    Bristol-Myers lung cancer delay slams shares, keeps Merck in lead Jan 20 2017
    Bristol-Myers lung cancer delay slams shares, keeps Merck in lead Jan 20 2017
    Bristol-Myers shares fall on lung cancer timeline setback Jan 20 2017
    Bristol-Myers shares fall on lung cancer timeline setback Jan 20 2017
    Is Neil Woodford a fool to continue pumping money into Capita plc and AstraZeneca plc? Jan 20 2017
    Blog Coverage AbbVie Received FDA Approval for Treatment for Marginal Zone Lymphoma Jan 20 2017
    [$$] GSK appoints AstraZeneca executive as global head of pharma Jan 19 2017
    This Could Be The Biggest Winner Of 2017’s Biotech Boom Jan 19 2017
    GSK grabs Astra executive to replace pharma head Jan 19 2017
    GSK grabs Astra executive to replace pharma head Jan 19 2017
    GSK grabs Astra executive to replace exiting pharma head Jan 19 2017
    GSK grabs Astra executive to replace exiting pharma head Jan 19 2017
    GSK grabs Astra executive to replace exiting pharma head Jan 19 2017
    3 top picks for a 2017 starter portfolio Jan 19 2017
    AstraZeneca Offers Update on Immuno-Oncology Program Jan 18 2017
    FDA Track Record Bodes Well For Merck Keytruda Plus Chemo: Leerink Jan 17 2017
    [$$] AstraZeneca expands trials for key cancer drug Jan 17 2017
    Dodge & Cox's Stock Fund 4th Quarter Commentary Jan 16 2017
    Bristol-Myers Threatens Merck's 'Head Start' In Lung Cancer: Analyst Jan 12 2017
    European Pharma Shares Hammered After Trump Press Conference Attack Jan 12 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)